Merck to Participate at the Morgan Stanley Global Healthcare Conference

Print

September 8, 2014 4:00 pm ET

Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that Kenneth C. Frazier, chairman and chief executive
officer; Adam H. Schechter, executive vice president and president,
Global Human Health; and Dr. Roy Baynes, senior vice president, Clinical
Development, Merck Research Laboratories, are scheduled to participate
at the Morgan Stanley Global Healthcare Conference in New York on Sept.
9, 2014 at 8:00 a.m. EDT. Investors, analysts, members of the media and
the general public are invited to listen to live audio presentation of
the webcasts at http://www.merck.com/investors/events-and-presentations/home.html.

About Merck

Today’s Merck is a global healthcare leader working to help the world be
well. Merck is known as MSD outside the United States and Canada.
Through our prescription medicines, vaccines, biologic therapies, and
consumer care and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access to
healthcare through far-reaching policies, programs and partnerships. For
more information, visit www.merck.com
and connect with us on Twitter,
Facebook
and YouTube.

Merck Forward-Looking Statement

This news release includes “forward-looking statements” within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. These statements are based
upon the current beliefs and expectations of Merck’s management and are
subject to significant risks and uncertainties. If underlying
assumptions prove inaccurate or risks or uncertainties materialize,
actual results may differ materially from those set forth in the
forward-looking statements.

Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; Merck’s ability to accurately
predict future market conditions; manufacturing difficulties or delays;
financial instability of international economies and sovereign risk;
dependence on the effectiveness of Merck patents and other protections
for innovative products; and the exposure to litigation, including
patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ
materially from those described in the forward-looking statements can be
found in Merck’s 2013 Annual Report on Form 10-K and the company’s other
filings with the Securities and Exchange Commission (SEC) available at
the SEC’s Internet site (www.sec.gov).

Merck
Media:
Lainie Keller, 308-423-4187
or
Investors:
Justin Holko, 908-423-5088

Unsubscribe from email alerts